1. Scrip
  2. >>Therapy Areas

Gazyva Succeeds In NOBILITY Lupus Nephritis Study But What Next?

 
• By Eleanor Malone

Genentech refrained from committing to further development of its CD20 inhibitor in the indication despite meeting endpoints in Phase II study.

Road_Arrows
Will Roche/Genentech proceed with Gazyva in lupus nephritis?

Genentech Inc.’s Gazyva (obinutuzumab) has met the primary endpoint in a Phase II trial studying it in adults with proliferative lupus nephritis, a severe kidney complication of the autoimmune disease systemic lupus erythematosus (SLE) for which there are no approved therapies in the US or EU.

The CD20-targeting drug, which was first approved by the US Food and Drug Administration in 2013 for chronic lymphocytic leukemia...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

More from Therapy Areas

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.